Reading SCNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SCNX free→Reading SCNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SCNX free→NASDAQHealth CarePharmaceutical RetailersSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent changes. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, SCNX is below typical. Peer multiples imply a price about 99% below where it trades (it looks expensive on this basis); the read is rich. The valuation is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.38. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.38 SCNX trades at 5× p/s — 2.0× the 3× p/s peer median. The market is re-rating it beyond its own range; our $0.19 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 99% near-term growth, in line with our forecast of about 100%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.66x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.23. 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$261.
How much price usually moves either way.
On a bad day, this stock has moved -$899.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $9,073.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Management rose by 11.6 points (from 12.1 to 23.7).
As of June 16, 2026, management rose. The sector backdrop remains a headwind. Risk is high, and earnings quality is characterized as loss-making. The overall situation is provisional, with potential unfavorable impacts from guidance cuts and sector trends weakening.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SCNX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Eric Sherb On May 26, 2026, Eric Sherb, the Chief Financial Officer (“CFO”) of Scienture Holdings, Inc. (the “Company”), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of direc…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SCNX SCIENTURE HOLDINGS INC | Below typical Show detailsSector percentile: 15 of 100 | expensive | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on the continued commercialization of Arbli TM and the anticipated launch of REZENOPY TM to impact business performance in 2026.
Newly stated in 2026-Q1. Management emphasized the impact of Arbli TM and REZENOPY TM on business performance for the second half of 2026. However, no specific revenue or volume milestones were provided, indicating limited substantive delivery so far.
“Continued commercialization of Arbli TM and anticipated launch of REZENOPY TM will impact performance in 2026.”
Entered into a note purchase agreement to issue secured promissory notes totaling $8.42 million.
Newly stated in 2026-Q1. The company addressed financial obligations by issuing $8.42 million in secured promissory notes. This capital allocation move is aimed at managing financial commitments, but the impact on overall financial health remains to be seen.
Transition in executive leadership with the resignation of CFO Eric Sherb.
Newly stated in 2026-Q1. The resignation of CFO Eric Sherb marks a significant executive transition. While the company states the resignation was for personal reasons, the impact on strategic direction and financial management is yet to be determined.
“CFO Eric Sherb resigned for personal reasons, not due to any dispute with the company.”
Results of Operations and Financial Condition. On May 18, 2026, Scienture Holdings, Inc. issued a press release announcing its financial results for the quarter ending March 31, 2026, and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes…
Entry into a Material Definitive Agreement. The information provided in
by reference. The information included in the Presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “ SEC ”) and other public announcements the Company has made or may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Current Report on Form 8-K (this “ Current Report ”). While the Company may elect to update the Presentation in the future to refle…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On April 27, 2026, Scienture Holdings, Inc. (the “ Company ”) entered into and closed on a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, (the “ Lender ”) providing for the issuance of two secured promissory notes: (i) a Secured Promissory Note A-1 in the original principal amount of $8.42 million (the “ A-1 Note ”) and (ii) a Secured Promis…
“Entered into a note purchase agreement for $8.42 million in secured promissory notes.”